1. Home
  2. BANX vs TNXP Comparison

BANX vs TNXP Comparison

Compare BANX & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANX

ArrowMark Financial Corp.

N/A

Current Price

$21.00

Market Cap

201.5M

Sector

Finance

ML Signal

N/A

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$11.66

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BANX
TNXP
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.5M
199.7M
IPO Year
2013
2008

Fundamental Metrics

Financial Performance
Metric
BANX
TNXP
Price
$21.00
$11.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
36.7K
413.1K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.75
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
N/A
$558.11
Revenue Next Year
N/A
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.85
52 Week Low
$18.45
$9.40
52 Week High
$23.67
$29.19

Technical Indicators

Market Signals
Indicator
BANX
TNXP
Relative Strength Index (RSI) 61.38 38.76
Support Level $21.01 $9.72
Resistance Level $21.29 $13.36
Average True Range (ATR) 0.26 0.73
MACD -0.00 -0.25
Stochastic Oscillator 75.53 4.81

Price Performance

Historical Comparison
BANX
TNXP

About BANX ArrowMark Financial Corp.

ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: